NovaBone

NovaBone, established in 2002, focuses on developing bone graft substitutes through biomedical engineering. The company's patented bioactive technology platform has led to the development of various formulations and delivery systems, resulting in accelerated bone growth. With over a million clinical applications in the past decade, NovaBone's bone graft substitute has been used successfully for repairing osseous defects throughout the skeletal system. Additionally, NovaBone® was the first bioactive synthetic bone graft offered to the orthopedic community and was authorized by the FDA in 2005 for its unique bone-forming process, known as "osteostimulation." The company operates in the Health Care and Health and Wellness industries. Despite lacking specific information regarding headquarters and recent investments, NovaBone has established itself as a leader in developing specialized solutions for orthopedic and dental surgeons.